Development of stable nanosuspensions: A strategy to improve the aqueous solubility of drugs

Poor aqueous and lipophilic solubility remains a significant bottleneck in pharmaceutical development. Nanosuspensions address this challenge by stabilizing submicron drug particles within a liquid phase using biocompatible surfactants or polymeric matrices. Lowering particle size into the nanometre range dramatically expands total surface area, driving higher dissolution kinetics and boosting systemic bioavailability. Formulation approaches generally fall into top-down mechanical attrition (such as high-pressure homogenization and media milling) or bottom-up molecular precipitation. Hybrid approaches like Nanoedge technology merge precipitation with homogenization to yield sub-micron systems with high physical stability and minimal crystal growth. Beyond oral administration, nanosuspensions facilitate non-invasive and targeted delivery across parenteral, pulmonary, ocular, and transdermal routes, including targeted delivery across the blood–brain barrier. Key quality attributes—such as particle size distribution, active content, encapsulation efficiency, and saturation solubility—are systematically evaluated to ensure performance. Overall, nanosuspensions represent a scalable, robust platform for delivering poorly soluble active pharmaceutical ingredients (APIs).